107 related articles for article (PubMed ID: 30220171)
21. [The influence of XRCC1 gene polymorphism on the prognosis and safety of stage Ⅲ patients with colorectal cancer who received oxaliplatin based adjuvant chemotherapy].
Li RX; Shang JH; Sun JF
Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(11):759-765. PubMed ID: 33765714
[No Abstract] [Full Text] [Related]
22. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
Koutras AK; Antonacopoulou AG; Eleftheraki AG; Dimitrakopoulos FI; Koumarianou A; Varthalitis I; Fostira F; Sgouros J; Briasoulis E; Bournakis E; Bafaloukos D; Bompolaki I; Galani E; Kalogeras KT; Pectasides D; Fountzilas G; Kalofonos HP
Pharmacogenomics J; 2012 Dec; 12(6):468-75. PubMed ID: 21844885
[TBL] [Abstract][Full Text] [Related]
23. Impact of MTHFR gene C677T polymorphism on Bcl-2 gene methylation and protein expression in colorectal cancer.
Zhu Q; Jin Z; Yuan Y; Lu Q; Ge D; Zong M
Scand J Gastroenterol; 2011 Apr; 46(4):436-45. PubMed ID: 21128871
[TBL] [Abstract][Full Text] [Related]
24. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
25. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.
Ulivi P; Scarpi E; Passardi A; Marisi G; Calistri D; Zoli W; Del Re M; Frassineti GL; Tassinari D; Tamberi S; Vertogen B; Amadori D
J Transl Med; 2015 Aug; 13():258. PubMed ID: 26259598
[TBL] [Abstract][Full Text] [Related]
26. IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.
Di Salvatore M; Pietrantonio F; Orlandi A; Del Re M; Berenato R; Rossi E; Caporale M; Guarino D; Martinetti A; Basso M; Mennitto R; Santonocito C; Mennitto A; Schinzari G; Bossi I; Capoluongo E; Danesi R; de Braud F; Barone C
Oncotarget; 2017 Mar; 8(10):16887-16898. PubMed ID: 28129643
[TBL] [Abstract][Full Text] [Related]
27. Rs11479 in
Jia X; Zhang T; Sun J; Lin H; Bai T; Qiao Y; Li Y; Li G; Li G; Peng X; Zhang A
Pharmgenomics Pers Med; 2023; 16():277-289. PubMed ID: 37025557
[TBL] [Abstract][Full Text] [Related]
28. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Schneider BP; Wang M; Radovich M; Sledge GW; Badve S; Thor A; Flockhart DA; Hancock B; Davidson N; Gralow J; Dickler M; Perez EA; Cobleigh M; Shenkier T; Edgerton S; Miller KD;
J Clin Oncol; 2008 Oct; 26(28):4672-8. PubMed ID: 18824714
[TBL] [Abstract][Full Text] [Related]
29. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP; Hufnagl C; Brechelmacher S; Huemer F; Hackl H; Rinnerthaler G; Romeder F; Monzo Fuentes C; Morre P; Hauser-Kronberger C; Mlineritsch B; Greil R
Pharmacogenomics J; 2017 Jul; 17(4):344-350. PubMed ID: 27139155
[TBL] [Abstract][Full Text] [Related]
30. A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis.
Zhang N; Huo Q; Wang X; Chen X; Long L; Guan X; Jiang L; Ma T; Hu W; Yang Q
Gene; 2014 Feb; 535(2):170-6. PubMed ID: 24316488
[TBL] [Abstract][Full Text] [Related]
31. Role of
Cui W; Li F; Yuan Q; Chen G; Chen C; Yu B
Oncotarget; 2017 Dec; 8(62):105472-105478. PubMed ID: 29285265
[TBL] [Abstract][Full Text] [Related]
32. Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients.
Sun K; Gong A; Liang P
Tumour Biol; 2015 Mar; 36(3):1549-59. PubMed ID: 25355595
[TBL] [Abstract][Full Text] [Related]
33. Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.
Vincenzi B; Zoccoli A; Schiavon G; Iuliani M; Pantano F; Dell'aquila E; Ratta R; Muda AO; Perrone G; Brunelli C; Correale P; Riva E; Russo A; Loupakis F; Falcone A; Santini D; Tonini G
Eur J Cancer; 2013 Apr; 49(6):1501-8. PubMed ID: 23266047
[TBL] [Abstract][Full Text] [Related]
34. [The association between polymorphism of transforming growth factor-β1 and radiochemotherapy response and survival in esophageal squamous cell carcinoma patients].
Zhou YL; Zhang WC; Chen XB; Xiao ZF; Qiao Y; Yu DK; Lin DX; Tan W
Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Jul; 45(7):583-7. PubMed ID: 22041558
[TBL] [Abstract][Full Text] [Related]
35. Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Zhang X; Fan J; Li Y; Lin S; Shu P; Ni J; Qin S; Zhang Z
Tumour Biol; 2016 Jan; 37(1):1061-9. PubMed ID: 26269114
[TBL] [Abstract][Full Text] [Related]
36. GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer.
Frey UH; Alakus H; Wohlschlaeger J; Schmitz KJ; Winde G; van Calker HG; Jöckel KH; Siffert W; Schmid KW
Clin Cancer Res; 2005 Jul; 11(14):5071-7. PubMed ID: 16033819
[TBL] [Abstract][Full Text] [Related]
37. Two SNPs of ATP-binding cassette B1 gene on the risk and prognosis of colorectal cancer.
Wang F; Huang Z; Zheng K; Zhao H; Hu W
Int J Clin Exp Pathol; 2015; 8(3):3083-9. PubMed ID: 26045821
[TBL] [Abstract][Full Text] [Related]
38. TT genotype of GNAS1 T393C polymorphism predicts better outcome of advanced non-small cell lung cancer patients.
Gong HY; Hu WG; Wang XL; Zhu F; Song QB
World J Gastrointest Oncol; 2014 Dec; 6(12):444-9. PubMed ID: 25516778
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of vascular endothelial growth factor polymorphisms in colorectal cancer patients.
do Espírito Santo GF; Galera BB; Duarte EC; Chen ES; Azis L; Damazo AS; Saba GT; de Sousa Gehrke F; Guerreiro da Silva ID; Waisberg J
World J Gastrointest Oncol; 2017 Feb; 9(2):78-86. PubMed ID: 28255429
[TBL] [Abstract][Full Text] [Related]
40. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival.
Paiva TF; de Jesus VH; Marques RA; da Costa AA; de Macedo MP; Peresi PM; Damascena A; Rossi BM; Begnami MD; de Lima VC
BMC Cancer; 2015 Sep; 15():643. PubMed ID: 26394830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
